Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Buy” by Analysts
Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) have received a consensus rating of “Buy” from the ten research firms that are presently covering the firm, Marketbeat reports. Ten investment analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have updated their coverage on […]
More Stories
Trump Says Thailand, Cambodia Agree to Cease-Fire After Calls With Leaders
By Tom Ozimek President Donald Trump said on Dec. 12 that Thailand and Cambodia had agreed to halt fighting along...
ICE Arrests 2,824, Deports 11,870 in New Orleans in November
By Naveen Athrappully The Immigration and Customs Enforcement (ICE) New Orleans field office arrested 2,824 illegal immigrants in November and...
What to Know About Trump’s New ‘Gold Card’ Visa Program
By Savannah Hulsey Pointer Applications opened on Dec. 10 for the Trump administration’s new Gold Card program that expedites visas...
Watchdog Finds 9 Large US Banks Actively Engaged in Debanking
By Naveen Athrappully Nine of the largest banks have been found to engage in debanking activities, according to preliminary findings...
US Coast Guard Operation Seizes 150,000 Pounds of Cocaine
By Naveen Athrappully More than 150,000 pounds of cocaine have been seized in the Eastern Pacific Ocean since the launch...
Number of Americans Receiving Unemployment Benefits Falls to 10-Month Low
By Andrew Moran The number of Americans collecting unemployment benefits has slipped to its lowest point in 10 months, the...